Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Mar 15, 2020; 12(3): 301-310
Published online Mar 15, 2020. doi: 10.4251/wjgo.v12.i3.301
Published online Mar 15, 2020. doi: 10.4251/wjgo.v12.i3.301
Table 1 Patient characteristics (n = 17)
| Patient characteristics | n (%) |
| Sex (male/female) | 9/8 (53/47) |
| Median age (range) | 63 (52-77) |
| Primary tumor site (colon/rectum) | 9/8 (53/47) |
| Number of previous anticancer therapies (III/IV/V) | 14/2/1 (82/12/6) |
| Mutational RAS status (mutated/wild type) | 13/4 (76/24) |
- Citation: Ricci V, Granetto C, Falletta A, Paccagnella M, Abbona A, Fea E, Fabozzi T, Lo Nigro C, Merlano MC. Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. World J Gastrointest Oncol 2020; 12(3): 301-310
- URL: https://www.wjgnet.com/1948-5204/full/v12/i3/301.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i3.301